Precigen, Inc. - Common Stock (PGEN) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
78
Good based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$5.12
Trend Context
Mixed / range
Latest briefing
What's happening with PGEN
fool.com15 Jul 2026
What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?
CFO Harry Thomasian Jr. sold 200,000 shares of Precigen common stock across two transactions for a total value of approximately $1.11 million, based on a weighted average price of $5.57 per share. This transaction reduced his direct ownership by 36%, leaving him with 354,535 shares directly held post-sale, representing an estimated $1.86 million as of the July 1, 2026 market close.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
seekingalpha.com26 Jun 2026
Precigen: Entering The Oncology 'Sweet Spot'
Precigen earns a STRONG BUY rating following the commercial success of PAPZIMEOS and rapid revenue growth. PGEN's AdenoVerse platform underpins a validated, scalable franchise, with PAPZIMEOS now endorsed as first-line therapy for RRP and covered by major US insurers. Management projects cash flow breakeven in 2026, with Wall Street revising EPS and revenue estimates sharply since the 1Q earnings call.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
accessnewswire.com15 Jun 2026
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
Meg Flippin, Benzinga Staff Writer Data reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rare respiratory disease GERMANTOWN, MD / ACCESS Newswire / June 15, 2026 / Precigen Inc. (NASDAQ:PGEN) has gained an important advantage in the marketing of its new treatment for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract. The commercial-stage precisio…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
fool.com
12 Jun 2026
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
